Ascendis Pharma A/S (ASND) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
ASND EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ASND Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 85.1% | -18.9% | -31.7% |
| 2024 | 87.8% | -76.7% | -104.0% |
| 2023 | 83.4% | -170.8% | -180.5% |
| 2022 | 76.3% | -1097.9% | -1139.6% |
| 2021 | 54.7% | -5808.6% | -4931.6% |
Download Data
Export ASND earnings history in CSV or JSON format
Free sign-in required to download data
Ascendis Pharma A/S (ASND) Earnings Overview
As of May 8, 2026, Ascendis Pharma A/S (ASND) reported trailing twelve-month net income of -$228M, reflecting +44.6% year-over-year growth. The company earned $-3.71 per diluted share over the past four quarters, with a net profit margin of -31.7%.
Looking at the long-term picture, ASND's historical earnings data spans multiple years. The company achieved its highest annual net income of $4M in fiscal 2013.
Ascendis Pharma A/S is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IONS (-$327M net income, -40.4% margin), INCY ($1.43B net income, 25.0% margin), ALKS ($153M net income, 16.4% margin), ASND has outperformed on profitability metrics. Compare ASND vs IONS →
ASND Earnings vs Peers
Earnings metrics vs comparable public companies
ASND Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$219M | +42.1% | -$131M | $-3.62 | -31.7% | -18.9% |
| 2024 | -$378M | +21.5% | -$279M | $-6.53 | -104.0% | -76.7% |
| 2023 | -$481M | +17.4% | -$456M | $-8.55 | -180.5% | -170.8% |
| 2022 | -$583M | -52.0% | -$562M | $-10.40 | -1139.6% | -1097.9% |
| 2021 | -$384M | +8.4% | -$452M | $-7.00 | -4931.6% | -5808.6% |
| 2020 | -$419M | -92.2% | -$331M | $-8.28 | -6025.5% | -4755.1% |
| 2019 | -$218M | -67.6% | -$227M | $-4.69 | -1630.0% | -1695.1% |
| 2018 | -$130M | -5.0% | -$155M | $-3.17 | -1229.5% | -1462.6% |
| 2017 | -$124M | -80.9% | -$112M | $-3.68 | -8097.8% | -7290.3% |
| 2016 | -$69M | -108.1% | -$73M | $-2.58 | -1487.3% | -1583.2% |
Full ASND Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See ASND's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ASND Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ASND vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonASND — Frequently Asked Questions
Quick answers to the most common questions about buying ASND stock.
Is ASND growing earnings?
ASND EPS is $-3.71, with earnings growth accelerating to +44.6%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-228M.
What are ASND's profit margins?
Ascendis Pharma A/S net margin is -31.7%, with operating margin at -18.9%. Below-average margins reflect competitive or cost pressures.
How consistent are ASND's earnings?
ASND earnings data spans 2012-2025. The accelerating earnings trend is +44.6% YoY. Historical data enables comparison across business cycles.